Dapagliflozin (Farxiga) was recently added to SJH formulary for the treatment of HFrEF in patients with or without diabetes. New starts during hospitalization require approval by cardiology (it does not require a formal consult, just a conversation). All SGLT2 inhibitors remain nonformulary for the sole indication of T2DM. We are excited to have this pillar of guideline directed medical therapy available for our patients. Please click here to familiarize yourself with the hospital’s policies for dapagliflozin.